Resource id #3DrugId:1d00000048resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   


Drug ID: 1d00000048

Drug Name: Alfuzosin

Generic Names: Efzu Ext | Flotral | Alfusin | Fual | Profuzo | Alfoo | Dutalfa | Zofu | Alfdo | Alfuzin | Xelflo | Uroxatral

Category: BPH Agents

Legal Status: Non Opioid Prescription only drug

OTC: No

Indication for Mother: Category B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Recommended Dose: The recommended dose is 2.5 mg 3 times/day. Max: 10 mg/day.

Recommended In: This medication is an alpha-blocker, prescribed for benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It works by relaxing the muscles in the prostate and bladder to allow urine to flow more easily.

Directions For Use: It comes as a tablet to take by mouth, with food.

Storage: Store it in a cool place (15-30C).

Dosage Forms: Tablet

Side Effects: Central Nervous System - Drowsiness, weakness, depression, headache, dizziness and lack of energy.

Heart - Low blood pressure, fainting, fast heart rate, palpitation, chest pain and flushing.

Gastrointestinal - Dry mouth and GI disturbances.

Miscellaneous - Swelling, blurred vision, runny nose, erectile disorders and hypersensitivity reactions.

In Case of Overdose: Should overdose of Alfuzosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then the administration of intravenous fluids should be considered. If necessary, vasopressors should then be used, and the renal function should be monitored and supported as needed. Alfuzosin is 82% to 90% protein bound; therefore, dialysis may not be of benefit.

Avoid If: Caution should be exercised in patients with history of irregular heartbeat, prostate cancer, chest pain, low blood pressure, heart or kidney disease, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.

It may cause drowsiness, dizziness or lightheadedness, do not drive a car or operate machinery and get up slowly from bed while taking this medication.

Avoid situations in which injury could occur because of fainting.

Rarely it may cause prolonged or painful erection; if it so consult with your doctor.

Contraindicated in patients with severe kidney, liver impairment, intestinal obstruction and hypersensitivity.

Drug Interaction: CYP3A4 Inhibitors

Alfuzosin is contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir, since alfuzosin blood levels are increased.

Alpha Adrenergic Antagonists

The pharmacokinetic and pharmacodynamic interactions between Alfuzosin and other alpha adrenergic antagonists have not been determined. However, interactions may be expected, and Alfuzosin should not be used in combination with other alpha adrenergic antagonists.

Antihypertensive Medication And Nitrates

There may be an increased risk of hypotension/postural hypotension and syncope when taking Alfuzosin concomitantly with anti-hypertensive medication and nitrates.

PDE5 Inhibitors

Caution is advised when alpha adrenergic antagonists, including Alfuzosin, are coadministered with PDE5 inhibitors. Alpha adrenergic antagonists and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension.



Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main